REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Women

The RECHARGE: Women Trial is a multicenter, 1:1 randomized, open-label superiority trial.

Patients meeting the eligibility criteria for whom there is equipoise for revascularization with CABG and PCI, as determined by the local Heart Team, will be included. Participants will be followed for 5-10 years. Telephone follow-up will be conducted by the a central follow-up coordinating center at 30 days, 3 months, 6 months, and thereafter every 6 months through 36 months post-randomization. After 36 months, follow-up will be performed every year (48, 60, 72, 84, 96, 108, 120 months). A repeat transthoracic echocardiogram and blood draw for serum creatinine, hemoglobin and lipids should be performed at 1 year, as per standard of care, at either an out-patient facility or in a hospital.

Inclusion criteria

• Female sex
• Patient is at least 18 years old.
• Multivessel or left main CAD is present for which revascularization is intended and for which there is equipoise between CABG and PCI according to local Heart Team assessment.
• Ability to provide written informed consent and comply with all follow-up procedures, including QOL questionnaires.

Exclusion criteria

• ST-segment elevation MI within 3 days
• Cardiogenic shock
• Prior PCI within 1 year or any prior CABG anytime
• Planned hybrid revascularization (PCI after CABG or CABG after PCI)
• Planned single vessel revascularization (other than isolated left main disease)
• Need for any cardiac surgical or interventional procedure other than coronary revascularization at the present time or anticipated within 3 years
• Pregnancy (women of child-bearing potential must have a negative pregnancy test within 1 week before randomization) or intent to become pregnant within 1 year after randomization
• Unable to tolerate, obtain or comply with dual antiplatelet therapy for at least 3 months if presentation with stable CAD or 6 months if presentation with a troponin-positive acute coronary syndrome
• Current participation in another investigational drug or device study that has not reached its primary endpoint
• Life-expectancy less than 3 years due to concomitant non-cardiac conditions
• Any condition(s) are present that are likely to interfere with the study protocol procedures including medication adherence and follow-up through 10 years (e.g. mental disability, substance abuse, anticipated international relocation, etc.)